3 files

Data from: Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency.

posted on 23.02.2021, 21:52 by Irina-Alexandra Bacila

Introduction: Monitoring of hormonal control represents a key part in the management of congenital adrenal hyperplasia (CAH). It remains suboptimal and relies on frequent blood tests, which are traumatising in children and young persons. We aimed to establish a non-invasive test for monitoring of adrenal-specific androgens in CAH.

Objective: To establish the correlation between plasma and salivary androgens in children with CAH.

Patients and Methods: Patients (n=78) and matched controls (n=62) were recruited in a multicentre prospective study of children with CAH across the United Kingdom. Using liquid chromatography tandem mass spectrometry, we measured plasma and salivary concentrations for five steroid hormones: 17-hydroxyprogesterone, androstenedione, testosterone, 11-hydroxyandrostenedione and 11-ketotestosterone and established the correlation between plasma and salivary steroids to assess their usefulness in clinical practice.

Results: Plasma and salivary steroid concentrations show a good correlation, with androstenedione and 11-ketotestosterone. In addition, a high correlation was found in patients with CAH when analysing subgroups based on gender and age. Clear differences can be found for all plasma and salivary steroids between patients and controls.

Conclusions: We have established the close correlation between plasma and salivary concentrations of steroid hormones assessed for therapy control CAH patients. Importantly, the best correlations were found for the adrenal-derived 11oxygenatedC19 androgen 11-ketotestosterone as well as 17-hydroxyprogesterone and androstenedione, which are widely used for CAH monitoring. Thus, we believe that this novel and improved combination of salivary steroid hormones can serve as non-invasive monitoring tool in CAH providing a significant amount of additional information and will ultimately improve management and outcomes in CAH.

The following files are included in the dataset (the supplementary figures and tables were revised in June 2019):

1. Supplementary figures (second revision) (1-6)

2. Supplementary tables (second revision) (1-10)

3. Supplementary information (sample collection protocols)


NIHR Rare Disease Translational Research Collaboration



There is no personal data or any that requires ethical approval


The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files